

2023 Material Information (6469 Great Tree)

Date of announcement	Subject	Statement
2023/02/23	Announcement on the 2022 Consolidated financial report made by Board of Directors	<ol style="list-style-type: none"> 1.Date of the board of directors submitted or approved:2023/02/23 2.Date of the audit committee approved:2023/02/23 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2022/01/01~2022/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):14,564,645 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):4,011,128 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):861,873 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):882,332 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):700,503 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):700,071 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):7.85 11.Total assets end of the period (thousand NTD):10,118,469 12.Total liabilities end of the period (thousand NTD):7,493,733 13.Equity attributable to owners of parent end of the period (thousand NTD):2,600,328 14.Any other matters that need to be specified:NA
2023/02/23	Great Tree Pharmacy Co., Ltd. Board of Directors approved dividend distribution	<ol style="list-style-type: none"> 1.Date of the board of directors resolution:2023/02/23 2.Year or quarter which dividends belong to :year 2022 3.Period which dividends belong to:2022/01/01~2022/12/31 4.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):NT\$4.70 5.Cash dividends distributed from legal reserve and capital reserve to shareholders (NT\$ per share):Nil 6.Total amount of cash dividends to shareholders (NT\$):NT\$422,522,017

Date of announcement	Subject	Statement
		<p>7.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):NT\$2.30</p> <p>8.Stock dividends distributed from legal reserve and capital reserve to shareholders (NT\$ per share):Nil</p> <p>9.Total amount of stock dividends to shareholders (shares):20,676,609</p> <p>10.Any other matters that need to be specified:None.</p> <p>11.Per value of common stock:NT\$10</p>
2023/02/23	Resolution to issue new shares for capital increase through profits by Board of Directors	<p>1.Date of the board of directors resolution:2023/02/23</p> <p>2.Source of capital increase funds:2022 profits</p> <p>3.Whether to adopt shelf registration(Yes, please state issuance period/No):No</p> <p>4.Total monetary value of the issuance and number of shares issued (shares issued not including those distributed to employees if consisting in capital increase from earnings or capital surplus):20,676,609 shares/206,766,090 NTD</p> <p>5.If adopting shelf registration, monetary value and number of shares to be issued this time:NA</p> <p>6.The remaining monetary value and shares after this issuance when adopting shelf registration:NA</p> <p>7.Par value per share:10 NTD</p> <p>8.Issue price:NA</p> <p>9.Number of shares subscribed for by or allocated to employees:NA</p> <p>10.Number of shares publicly sold:NA</p> <p>11.Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: The shareholders will be entitled to receive 230 shares for each 1,000 shares.</p> <p>12.Handling method for fractional shares and shares unsubscribed for by the deadline: The existing shareholders may apply by themselves to combine fractional share of less than one share into one share within five days after the basis date of dividend distribution. If abandoned to combine or cannot be combined into one share, such fractional shares will be purchased by persons arranged by the Chairman as authorized by the BOD.</p>

Date of announcement	Subject	Statement
		<p>13.Rights and obligations of these newly issued shares: same as existing shares</p> <p>14.Utilization of the funds from the capital increase: to increase the operational capital</p> <p>15.Any other matters that need to be specified:</p> <p>(1)If there is any outstanding shares changed due to the change of the Company's capital stock, the Shareholders' meeting empowers the Board of Directors to handle.</p> <p>(2)Upon the approval of the Annual Shareholders' Meeting and the competent authorities, it is proposed that the Board of Directors be authorized to resolve the ex-rights date to distribute.</p>
2023/02/23	Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to conduct private placement of common shares	<p>1.Date of the board of directors resolution:2023/02/23</p> <p>2.Types of securities privately placed:Common shares</p> <p>3.Counterparties for private placement and their relationship with the Company:</p> <p>(1)The counterparties for this private placement shall meet the qualifications for specific persons listed in Article 43-6 of the Securities and Exchange Act, and are limited to strategic investors, prioritizing those who could benefit the Company's long-term development, competitiveness, and rights of existing shareholders.</p> <p>(2)In order to enhance competitiveness, increase operating efficiency and long-term development, strategic investors can directly or indirectly improve the Company's the finance, business ,brand ,market share, purchase, management and development.</p> <p>(3)The Company has not found specific persons yet and is proposed to authorize the Board of Directors to find specific persons and handle related matters.</p>

Date of announcement	Subject	Statement
		<p>4.Number of shares or bonds privately placed: It will be proposed for the shareholders meeting to authorize the Board of Directors to choose appropriate timing and fund fundraising instrument(s) by one or a combination of methods:conduct private placement of common shares and/or conduct private placement of domestic convertible corporate bonds, within the limit of 2 million common shares, depending on the market conditions and the Company's needs, in accordance with the applicable laws and regulations and the following fund raising method principles.When domestic convertible corporate bonds are issued through private placement, the number of common shares that can be converted from privately placed convertible corporate bonds shall be within the aforementioned scope of 2 million shares, and shall be calculated in accordance with the conversion price determined at the time of private placement.</p> <p>5.Amount limit of the private placement: To be determined</p> <p>6.Pricing basis of private placement and its reasonableness: (1)The issue price of the privately placed common shares shall not be lower than 80 percent of the reference price. The reference price shall be the higher of the following two calculations: A.The simple average closing price of the common shares for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction. B.The simple average closing price of the common shares for the 30</p>

Date of announcement	Subject	Statement
		<p>business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.</p> <p>(2)The setting of the privately placed domestic unsecured convertible corporate bonds price is not lower than 80 percent of the reference price, the setting method of which is compliance with the existing laws and regulation; hence, it is of resonability.The reference price for calculation and the actual conversion price shall be the higher of the following two calculations:</p> <p>A.The simple average closing price of the common shares for either the 1. 3, or 5 business days before the price determination date, after adjustment for any distrubution of stock dividends, cash dividends or capital reduction.</p> <p>B.The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash divedends, or capital reduction.</p> <p>(3)The subscription price for common shares of this private placement shall be determined with reference to the price of the Company's common shares, in accordance with the Direcions for Public Companies Conducting Private Placements of Securities. Thus, the price should be reasonable.</p> <p>7.Use of the funds raised in the private placement: The funds raised hereby shall serve to either increase working capital, strengthen the financial structure and support the company to expand its</p>

Date of announcement	Subject	Statement
		<p>marketing channels increase its market share.</p> <p>8.Reasons for conducting non-public offering: Based on the status of the capital market, timeliness and feasibility of fundraising, issuance cost, and the actual needs to attract strategic investors. Privately placed securities cannot be freely traded within three years, can ensure the long-term cooperation between the Company and strategic investors, and authorizing the Board of Directors to conduct private placement according to the Company's actual business needs effectively increases flexibility and freedom for fundraising.</p> <p>9.Objections or qualified opinions from independent Board of Directors: None</p> <p>10.Actual price determination date: N/A</p> <p>11.Reference price: N/A</p> <p>12.Actual private placement price, and conversion or subscription price: N/A</p> <p>13.Rights and obligations of these new shares privately placed: The rights and obligations of the privately placed common shares are the same with the issued common shares. Except for the transfer restriction on objects regulated by Article 43-8, Securities and Exchange Act, privately placed securities in principle may not be transferred until three full years after the delivery date. The Board of Directors is intended to be authorized by a special shareholders meeting and may be filed with the Competent Authority for retroactive handling of public issuance procedures and listing where three full years have elapsed since the delivery date.</p> <p>14.Reference date for any additional share exchange, stock swap, or subscription: N/A</p>

Date of announcement	Subject	Statement
		<p>15.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: N/A</p> <p>16.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEX -listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEX -listed common shares (a), (a) / outstanding common shares): N/A</p> <p>17.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEX – listed common shares does not reach 5 million and the ratio does not reach 25%: N/A</p> <p>18.Any other matters that need to be specified: None.</p>
2023/02/23	Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to conduct private placement of domestic convertible corporate bonds	<p>1.Date of the board of directors resolution:2023/02/23</p> <p>2.Name of the corporate bonds: Domestic convertible corporate bonds in private placement</p> <p>3.Total amount issued: It will be proposed for the shareholders meeting to authorize the Board of Directors to choose appropriate timing and fund fundraising instrument(s) by one or a combination of methods:conduct private placement of common shares and/or conduct private placement of domestic convertible corporate bonds, within the limit of 2 million common shares, depending on the market conditions and the Company's needs, in accordance with the applicable laws and regulations and the following fund raising method principles. When domestic convertible corporate bonds are issued through private placement, the number of common shares that can be converted from privately placed convertible corporate bonds shall be within the aforementioned scope of 2 million shares, and shall be calculated in accordance with the conversion price determined at the time of private placement.</p> <p>4.Face value per bond: par value of NT\$100,000</p>

Date of announcement	Subject	Statement
		<p>5.Issue price: The issue price shall be no less than 80% of the theoretical price.</p> <p>6.Issuance period: The Board of Directors is authorized to determine this.</p> <p>7.Coupon rate: The Board of Directors is authorized to determine this.</p> <p>8.Types, names, monetary values and stipulations of collaterals: N/A</p> <p>9.Use of the funds raised by the offering and utilization plan: The funds raised hereby shall serve to either increase working capital, strengthen the financial structure and support the company to expand its marketing channels increase its market share.</p> <p>10.Trustees of the corporate bonds: N/A</p> <p>11.Guarantor(s) for the issuance: N/A</p> <p>12.Agent for payment of the principal and interest: N/A</p> <p>13.Where convertible into shares, the price and the rules for conversion: The Board of Directors is authorized to determine this.</p> <p>14.Sell-back conditions: The Board of Directors is authorized to determine this.</p> <p>15.Buyback conditions: The Board of Directors is authorized to determine this.</p> <p>16.Reference date for any additional share exchange, stock swap, or subscription: N/A</p> <p>17.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: N/a</p> <p>18.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEX-listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEX -listed common shares (a),(a) / outstanding common shares): N/A</p> <p>19.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEX-listed common shares does not reach 5 million and the ratio does not reach 25%: N/A</p>

Date of announcement	Subject	Statement
		<p>20.Any other matters that need to be specified:</p> <p>(1)Except for the transfer restriction regulated by Article 43-8, Securities and Exchange Act, the rights and obligations of the new privately placed common shares converted from domestic convertible bonds are the same as the issued common shares.</p> <p>Privately placed securities in principle may not be transferred and may be filed with the Competent Authority for retroactive handling of public issuance procedures and listing where three full years have elapsed since the delivery date.</p> <p>(2)It will be submitted to a shareholders meeting that the Chairman is authorized with full power to adjust, determine, and conduct the important part of the plan for privately placed domestic convertible bonds, such as terms and conditions of issuance, particulars of the plan, funds to be raised, the purpose of the funds, implementation schedule, and expected returns, and so on, due to the instruction or requirement from the Competent Authority or to the necessary amendment or adjustment in response to objective factors.</p> <p>Besides the aforementioned authorization, the Chairman intends to obtain the authorization by a shareholders meeting to sign and negotiate the contracts and documents related to this private placement plan on behalf of the Company and to handle all matters for this private placement plan.</p>
2023/02/24	The Board of Directors approved the 2022	<p>1.Date of occurrence of the event:2023/02/23</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p>

Date of announcement	Subject	Statement
	distributable compensation for employees and directors.	<p>3.Relationship to the Company (please enter "head office" or"subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:not applicable</p> <p>5.Cause of occurrence:In accordance with the order No.1050001900 issued by FSC on 2016/01/30</p> <p>6.Countermeasures:not applicable</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):</p> <p>(1)The sum of directors' compensation:5,072,484 NTD</p> <p>(2)The sum of employees' compensation:26,697,284 NTD</p> <p>(3)The employees' and directors' compensation was distributed by cash.</p> <p>(4)The above numbers are the same as the recognized expense of 2022.</p>
2023/02/24	Due to internal reorganization within Ernst& Young , change of Certified Public Accountant will take place in the first quarter of 2023	<p>1.Date of the board of directors resolution (Date of occurrence of the event):2023/02/23</p> <p>2.Name of the original accounting firm:Ernst&Young</p> <p>3.Name of the original CPA 1:Lo Hsiao Chin</p> <p>4.Name of the original CPA 2:Hung Mao Yi</p> <p>5.Name of the new accounting firm:Ernst&Young</p> <p>6.Name of the new CPA 1:Lo Hsiao Chin</p> <p>7.Name of the new CPA 2:Chang Chih Ming</p> <p>8.Reason for the replacement: The internal reorganization of accounting firm.</p> <p>9.Specify whether the company or the original CPA decided to terminate or discontinue the appointment:N/A</p> <p>10.The date the company notified or was notified by the CPA about the termination:2023/02/23</p> <p>11.Were there adjustments to or suggestions on major internal control improvement matters in financial report that have been filed or are being prepared in the last 2 fiscal years:N/A</p> <p>12.Was there any divergence in opinion between the Company and the original CPA concerning above adjustments or</p>

Date of announcement	Subject	Statement
		<p>suggestions? (If so, please specify.):N/A</p> <p>13.Whether the company consults the new CPA regarding the adjustments and suggestions and probable opinion before official engagement? (If so, please specify.):N/A</p> <p>14.Specify whether the original CPA is authorized to respond to the reasonable inquiries (including diverging opinions on above matters) from the new CPA:N/A</p> <p>15.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 7 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):N/A</p>
2023/02/24	Great Tree Pharmacy Co., Ltd.'s Board of Directors approved the convening of the 2023 Annual Shareholders' Meeting	<p>1.Date of the board of directors resolution:2023/02/23</p> <p>2.General shareholders' meeting date:2023/05/31</p> <p>3.General shareholders' meeting location:Great Tree Pharmacy Co., Ltd. (17F.,No.186, Fuxing Rd., Taoyuan Dist., Taoyuan Dist., Taoyuan City)</p> <p>4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting):physical shareholders meeting</p> <p>5.Cause for convening the meeting I.Reported matters:</p> <p>(1)To report the business report of 2022.</p> <p>(2)To report the Audit Committee's review report of 2022.</p> <p>(3)To report the compensation to employees and remuneration to directors of 2022.</p> <p>(4)To accept the proposal for distribution of 2022 earnings(cash dividend).</p> <p>(5)Report on issuance of the Company's first domestic privately placed unsecured convertible bonds in 2022.</p> <p>(6)Report on issuance of the Company's 2nd domestic unsecured convertible bonds in 2022.</p> <p>6.Cause for convening the meeting II.Acknowledged matters:</p> <p>(1)To accept 2022 Business Report and Financial Statements.</p> <p>(2)To accept the proposal for distribution of 2022 earnings.</p>

Date of announcement	Subject	Statement
		<p>7.Cause for convening the meeting III.Matters for Discussion: (1)Proposal for a new share issue thorough capitalization for earnings. (2)Amendment to the Company's "Article of Incorporation". (3)Amendment to the Company's "Regulations Governing the Acquisition and Disposal of Assets". (4)Discussion of private placement of common shares and/or private placement of domestic convertible corporate bonds.</p> <p>8.Cause for convening the meeting IV.Election matters: (1)Election of the 4th Directors(including Independent Directors)</p> <p>9.Cause for convening the meeting V.Other Proposals: (1)Proposal for releasing the prohibition on Directors from participation in competitive business.</p> <p>10.Cause for convening the meeting VI.Extemporary Motions:not applicable.</p> <p>11.Book closure starting date:2023/04/02 12.Book closure ending date:2023/05/31 13.Any other matters that need to be specified: (1)According to article 172-1 of Company Act, the company accepts proposals and the nomination of director candidates from shareholder in the period between 2023/03/27 and 2023/04/06. Addressed:Great Tree Pharmacy Co., Ltd. 's head office.(18F,No.186, Fuxing Rd., Taoyuan Dist.,Taoyuan City) (2)The company's convertible bonds is suspended from 2023/04/02 to 2023/05/31, If bondholders intend to apply for conversion due to the holiday, they should contact the securities company on 2023/03/30 at the latest. Go through the conversion procedure.</p>
2023/03/02	Clarification of Media	1.Date of occurrence of the event:2023/03/01

Date of announcement	Subject	Statement
	Reports	<p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:CMoney</p> <p>6.Content of the report: The media news headlines 「 Great Tree Pharmacy's 2022 annual profit hit a record high again, and its stock price soars by more than 8% 」 「 ...It is estimated that the revenue in 2023 will challenge NTD 17.9 billion, and the EPS will challenge NTD 9.71, and the current P/E ratio is about 37.3X. As Great Tree's 2023 sotre has a clear goal and the three-crossing plan will continue to increase the rate of exhibition stores.The development of operation development is optimistic, and believes that the P/E ratio is expected to move closer to 42X. 」</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by investor news based on the company's released monthly revenue. The actual financial results shall be referred to the Company's offical announcements.</p> <p>9.Any other matters that need to be specified:None</p>
2023/03/08	The company is invited to the investment	<p>1.Date of institutional investor conference:2023/03/03</p> <p>2.Time of institutional investor conference:14:30</p>

Date of announcement	Subject	Statement																				
	forum held by Fubon Securities	3.Location of institutional investor conference: No.88, Yanchang Rd., Xinyi Dist., Taipei City 4.Outline of institutional investor conference: To present Great Tree's operating results and future outlook to the institutional investors. 5.Any other matters that need to be specified:None.																				
2023/03/08	The company is invited to the investment forum held by Taipei Exchange	1.Date of institutional investor conference:2023/03/27 2.Time of institutional investor conference:15:00 3.Location of institutional investor conference: Taipei Garden Hotel (2F, No.1,Sec.2,Zhonghua Rd.,Zhongzheng District, Taipei City) 4.Outline of institutional investor conference: To present Great Tree's operating results and future outlook to the institutional investors. 5.Any other matters that need to be specified:None.																				
2023/03/16	Announcement of the Company's recent financial information due to abnormal stock trading in TPEX	1.Date of occurrence of the event:2023/03/16 2.Cause of occurrence:Handled according to the notice from TPEX 3.Financial and business information:(Consolidated; NT\$:million) Monthly: <table border="1" data-bbox="672 957 1724 1388"> <thead> <tr> <th></th> <th>(2023)1</th> <th>(2022)1</th> <th>YOY increase/(decrease)(%)</th> </tr> </thead> <tbody> <tr> <td>Sales Revenue</td> <td>1,345</td> <td>1,142</td> <td>17.78%</td> </tr> <tr> <td>Profit before income tax</td> <td>81</td> <td>58</td> <td>39.66%</td> </tr> <tr> <td>Profit for the period</td> <td>65</td> <td>46</td> <td>41.30%</td> </tr> <tr> <td>Earnings per share(dollar)</td> <td>0.73</td> <td>0.52</td> <td>40.38%</td> </tr> </tbody> </table>		(2023)1	(2022)1	YOY increase/(decrease)(%)	Sales Revenue	1,345	1,142	17.78%	Profit before income tax	81	58	39.66%	Profit for the period	65	46	41.30%	Earnings per share(dollar)	0.73	0.52	40.38%
	(2023)1	(2022)1	YOY increase/(decrease)(%)																			
Sales Revenue	1,345	1,142	17.78%																			
Profit before income tax	81	58	39.66%																			
Profit for the period	65	46	41.30%																			
Earnings per share(dollar)	0.73	0.52	40.38%																			

Date of announcement	Subject	Statement		
		Accumulated over		
		the last 2 months: (2022)12- (2021)12-		
		(2023)1	(2022)1	YOY increase/(decrease)(%)
		-----	-----	-----
	Sales Revenue	2,622	2,140	22.52%
	Profit before income tax	189	119	58.82%
	Profit for the period	151	95	58.95%
	Earnings per share(dollar)	1.69	1.08	56.48%
	Quarterly:	(2022)Q4	(2021)Q4	YOY increase/(decrease)(%)
		-----	-----	-----
	Sales Revenue	3,792	3,054	24.17%
	Profit before income tax	211	142	48.59%
	Profit for the period	168	112	50.00%
	Earnings per share(dollar)	1.88	1.28	46.88%
	Accumulated over			
	the last 4 quarters:	(2022)Q1~(2022)Q4		

	Sales Revenue	14,565		

Date of announcement	Subject	Statement
	headquarters	<p>4.Reciprocal shareholding ratios:NA</p> <p>5.Cause of occurrence: Due to the business demand that all departments of head office move to the new operational headquarters and work over there, the Board of Directors resolved to change the Company's registered business address on November 11,2021. Besides, this proposal has been approved through the document MOEA-license-trade-No. 11230042890 issued by Ministry of Economic Affairs on March 23,2023. The actual movement is completed today.</p> <p>6.Countermeasures: (1)Announce related information on the website of MOPS. (2)Proceed the amendment registration of new address and related matters to the competent authority in accordance with the laws.</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1)Original address and swithboard before amendment: No.143 Chengzhang 4th St., Zhongli Dist., Taoyuan City, Taiwan; +886(3)433-3123 (2)New address and swithboard after amendment: 18F,No.186, Fuxing Rd., Taoyuan Dist., Taoyuan City, Taiwan; +886(3)433-3123</p>
2023/05/10	Announcement on the 2023Q1 Consolidated financial report made by Board of Directors	<p>1.Date of the board of directors submitted or approved:2023/05/10</p> <p>2.Date of the audit committee approved:2023/05/10</p> <p>3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2023/01/01~2023/03/31</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,814,083</p>

Date of announcement	Subject	Statement
		5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,048,017 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):187,268 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):198,010 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):156,918 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):156,848 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.74 11.Total assets end of the period (thousand NTD):9,954,921 12.Total liabilities end of the period (thousand NTD):7,585,807 13.Equity attributable to owners of parent end of the period (thousand NTD):2,344,672 14.Any other matters that need to be specified:NA
2023/05/31	Announcement of the resolution to distribute dividends, on behalf of major subsidiary Chang Chun Teng Biotechnology Corporation Ltd.	1.Date of the board of directors resolution:2023/05/31 2.Type and monetary amount of dividend distribution: Cash Dividends NT\$102,778,000 3.Any other matters that need to be specified:None.
2023/05/31	Announcement of the resolution to distribute dividends, on behalf of major subsidiary Bai Lin Logistics Co., Ltd.	1.Date of the board of directors resolution:2023/05/31 2.Type and monetary amount of dividend distribution: Cash Dividends NT\$4,900,000 3.Any other matters that need to be specified:None.
2023/05/31	Announcement the Important resolutions of the	1.Date of the shareholders' meeting:2023/05/31 2.Important resolutions I.Profit distribution/deficit compensation:

Date of announcement	Subject	Statement
	2023 Shareholders' Meeting	<p>Agreed to endorsed fiscal 2022 profit distribution.</p> <p>3.Important resolutions II.Amendments of the company charter: Passed the amendments to the Company's "Articles of Incorporation".</p> <p>4.Important resolutions III.Business report and financial statements: Agreed to endorsed fiscal 2022 business report and financial statements.</p> <p>5.Important resolutions IV.Election for directors and supervisors: List of Directors elected Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng Top Taiwan XI Venture Capital Co., Ltd. Hung-Yi Chen Shan-Feng Lu Legal Representative of Hao Cheng Investment Co., Ltd. : Shi-Wei Ye List of Independent Directors elected Tian-Dao Liu Dai-Huang Kuo Hsing-Wen Wang Min-Hsiung Pan</p> <p>6.Important resolutions V.Other matters: A.To approve new share issue through capitalization of earnings. B.Passed the amendments to the Company's "Regulations Governing the Acquisition and Disposal of Assets". C.Passed the proposed private placement of common shares and/or private placement of domestic convertible corporate bonds. D.Approved the proposal to release the newly elected Directors and their</p>

Date of announcement	Subject	Statement
		<p>representatives from non-competition restrictions.</p> <p>7.Any other matters that need to be specified:None.</p>
2023/05/31	The Company's re-election of Directors and Independent directors at 2023 Annual General Shareholders' Meeting	<p>1.Date of occurrence of the change:2023/05/31</p> <p>2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director,independent director and natural-person director</p> <p>3.Title and name of the previous position holder:</p> <p>Director Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng Director Top Taiwan XI Venture Capital Co., Ltd. Director Huang-Yi Chen Director Shan-Feng Lu Independent director Tian-Dao Liu Independent director Dai-Huang Kuo Independent director Hsing-Wen Wang</p> <p>4.Resume of the previous position holder:</p> <p>Director Legal Representative of Zhen Han Invsetment Co., Ltd. : Ming-Lung Cheng Chairman and General Manager of the Company Director Top Taiwan XI Venture Capital Co., Ltd. Director of Stement Biotherapeutics Inc. Director Huang-Yi Chen Professor of the Department of Pharmacy, Chinese Medical University Director Shan-Feng Lu Director and Deputy General Manager of the Company Independent director Tian-Dao Liu Certified Public Accountant of Zhi-Dao Accounting Firm Independent director Dai-Huang Kuo Professor of the Department of Pharmacy and Institute of Pharmacy and President of Tajen University</p>

Date of announcement	Subject	Statement
		<p>Independent director Hsing-Wen Wang Chief Lawyer of Hsing-Wen Wang Law Firm</p> <p>5.Title and name of the new position holder:</p> <p>Director Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng</p> <p>Director Top Taiwan XI Venture Capital Co., Ltd.</p> <p>Director Huang-Yi Chen</p> <p>Director Shan-Feng Lu</p> <p>Director Legal Representative of Hao Cheng Investment Co., Ltd. : Shi-Wei Ye</p> <p>Independent director Tian-Dao Liu</p> <p>Independent director Dai-Huang Kuo</p> <p>Independent director Hsing-Wen Wang</p> <p>Independent director Min-Hsiung Pan</p> <p>6.Resume of the new position holder:</p> <p>Director Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng Chairman and General Manager of the Company</p> <p>Director Top Taiwan XI Venture Capital Co., Ltd. Director of Steminent Biotherapeutics Inc.</p> <p>Director Huang-Yi Chen Professor of the Department of Pharmacy, Chinese Medical University</p> <p>Director Shan-Feng Lu Director and Deputy General Manager of the Company</p> <p>Director Legal Representative of Hao Cheng Investment Co., Ltd. : Shi-Wei Ye Associate Director of the Product Purchase and Marketing Department of the Company</p> <p>Independent director Tian-Dao Liu Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>Independent director Dai-Huang Kuo Professor of the Department of Pharmacy and Institute of Pharmacy and President of Tajen University</p> <p>Independent director Hsing-Wen Wang Chief Lawyer of Hsing-Wen Wang Law Firm</p>

Date of announcement	Subject	Statement
		<p>Independent director Min-Hsiung Pan Professor and Director of the Institute of Food Science and Technology of NTU</p> <p>7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):term expired</p> <p>8.Reason for the change:term expired and re-election</p> <p>9.Number of shares held by the new position holder when elected:</p> <p>Director Legal Representative of Zhen Han Invetsment Co., Ltd. :</p> <p style="padding-left: 40px;">Ming-Lung Cheng 9,885,264 shares</p> <p>Director Top Taiwan XI Venture Capital Co., Ltd. 443,403 shares</p> <p>Director Huang-Yi Chen 0 shares</p> <p>Director Shan-Feng Lu 914,640 shares</p> <p>Director Legal Representative of Hao Cheng Investment Co., Ltd. :</p> <p style="padding-left: 40px;">Shi-Wei Ye 6,897,715 shares</p> <p>Independent director Tian-Dao Liu 0 shares</p> <p>Independent director Dai-Huang Kuo 58,725 shares</p> <p>Independent director Hsing-Wen Wang 0 shares</p> <p>Independent director Min-Hsiung Pan 0 shares</p> <p>10.Original term (from _____ to _____):2020/06/17~2023/06/16</p> <p>11.Effective date of the new appointment:2023/05/31</p> <p>12.Turnover rate of directors of the same term:NA</p> <p>13.Turnover rate of independent directors of the same term:NA</p> <p>14.Turnover rate of supervisors of the same term:NA</p> <p>15.Change in one-third or more of directors (Please enter “Yes” or “No”):No</p> <p>16.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement</p>

Date of announcement	Subject	Statement
		Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.
2023/05/31	The Chairperson is elected by the board of directors	<p>1.Date of the board of directors resolution or date of occurrence of the change:2023/05/31</p> <p>2.Position (Please enter chairperson or president/general manager):chairperson</p> <p>3.Name of the previous position holder: Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng</p> <p>4.Resume of the previous position holder: Chairman and General Manager of the Company</p> <p>5.Name of the new position holder: Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng</p> <p>6.Resume of the new position holder: Chairman and General Manager of the Company</p> <p>7.Circumstances of change (Please enter "resignation", "dismissal", " term expired" , "job relocation", "severance", "retirement", " death" or "new appointment"):term expired</p> <p>8.Reason for the change:The general shareholders'meeting re-elects the directors, and the new board of directors elects the chairman.</p> <p>9.Effective date of the new appointment:2023/05/31</p> <p>10.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.</p>
2023/05/31	Announcement of member change of the Audit Committee and the	<p>1.Date of occurrence of the change:2023/05/31</p> <p>2.Name of the functional committees: Audit Committee and Remuneration Committee</p> <p>3.Name of the previous position holder:</p>

Date of announcement	Subject	Statement
	Remuneration Committee	<p>Independent director Tian-Dao Liu</p> <p>Independent director Dai-Huang Kuo</p> <p>Independent director Hsing-Wen Wang</p> <p>4.Resume of the previous position holder:</p> <p>Independent director Tian-Dao Liu Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>Independent director Dai-Huang Kuo Professor of the Department of Pharmacy and Institute of Pharmacy and President of Tajen University</p> <p>Independent director Hsing-Wen Wang Chief Lawyer of Hsing-Wen Wang Law Firm</p> <p>5.Name of the new position holder:</p> <p>Independent director Tian-Dao Liu</p> <p>Independent director Dai-Huang Kuo</p> <p>Independent director Hsing-Wen Wang</p> <p>Independent director Min-Hsiung Pan</p> <p>6.Resume of the new position holder:</p> <p>Independent director Tian-Dao Liu Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>Independent director Dai-Huang Kuo Professor of the Department of Pharmacy and Institute of Pharmacy and President of Tajen University</p> <p>Independent director Hsing-Wen Wang Chief Lawyer of Hsing-Wen Wang Law Firm</p> <p>Independent director Min-Hsiung Pan Professor and Director of the Institute of Food Science and Technology of NTU</p> <p>7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):term expired</p> <p>8.Reason for the change:Due to re-election of directors by the shareholders, the change of members for Audit Committee and Remuneration Committee</p>

Date of announcement	Subject	Statement
		<p>are required.</p> <p>9.Original term (from _____ to _____):2020/06/17~2023/06/16</p> <p>10.Effective date of the new member:2023/05/31</p> <p>11.Any other matters that need to be specified:None.</p>
2023/05/31	The Company's 2023 Annual General Shareholders' meeting approved to release the newly elected Directors and their representatives from non-competition	<p>1.Date of the shareholders' meeting resolution:2023/05/31</p> <p>2.Name and title of the managerial officer with permission to engage in competitive conduct:</p> <p>a.Director Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng</p> <p>b.Director Top Taiwan XI Venture Capital Co., Ltd.</p> <p>c.Director Shan-Feng Lu</p> <p>d.Director Legal Representative of Hao Cheng Investment Co., Ltd. : Shi-Wei Ye</p> <p>3.Items of competitive conduct in which the officer is permitted to engage:</p> <p>a.Director Legal Representative of Zhen Han Investment Co., Ltd. : Ming-Lung Cheng</p> <p>Director of Tree Top Molecular Biotechnology Co., Ltd.</p> <p>Chairman of Da Yu Property Management Co., Ltd.</p> <p>Chairman of Zhen Han Investment Co., Ltd.</p> <p>Chairman of Hao Cheng Investmnet Co., Ltd.</p> <p>b.Director Top Taiwan XI Venture Capital Co., Ltd.</p> <p>Director of Steminent Biotherapeutics Inc.</p> <p>Director of TaiHao Medical Inc.</p> <p>Director of TRUST BIO-SONICS INC.</p>

Date of announcement	Subject	Statement
		<p>c. Director Shan-Feng Lu Chairman of Great Tree Pets Co., Ltd. Director Legal Representative of GREAT TREE INTERNATIONAL SDN.BHD.</p> <p>d. Director Legal Representative of Hao Cheng Investment Co., Ltd. : Chairman of Bai Lin Logistics Co., Ltd. Director Legal Representative of Great Tree Pets Co., Ltd.</p> <p>4. Period of permission to engage in the competitive conduct: the period of being the Company's Director.</p> <p>5. Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Approved by a majority of the shareholder, respectively, who are present and represent two-thirds or more of the total number of its outstanding shares. The proposal was approved as proposed.</p> <p>6. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter "N/A" below): N/A</p> <p>7. Company name of the mainland China enterprise and the officer's position in the enterprise: N/A</p> <p>8. Address of the mainland China enterprise: N/A</p> <p>9. Operations of the mainland China enterprise: N/A</p> <p>10. Impact on the company's finance and business: None.</p> <p>11. If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: N/A</p> <p>12. Any other matters that need to be specified: None.</p>
2023/06/05	Announcement on the	1. Date of the resolution by the board of directors or shareholders' meeting, or of the decision by the

Date of announcement	Subject	Statement
	ex-dividend base date and distribution date set by the chairman of the company	<p>company:2023/06/05</p> <p>2.Type (ex-rights or ex-dividend) (please write "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"):Ex-dividend</p> <p>3.Type and monetary amount of dividend distribution: Cash dividends to common shareholders NT\$422,522,017</p> <p>4.Ex-rights (Ex-dividend) date:2023/07/05</p> <p>5.Last date before book closure:2023/07/06</p> <p>6.Book closure starting date:2023/07/07</p> <p>7.Book closure ending date:2023/07/11</p> <p>8.Ex-rights (Ex-dividend) record date:2023/07/11</p> <p>9.Deadline for applying the conversion of the debt voucher:2023/06/12</p> <p>10.The closure period for the conversion of the debt voucher will start from the date:2023/06/14</p> <p>11.The closure period for the conversion of the debt voucher will end on the date:2023/07/11</p> <p>12.Payment date of cash dividend distribution:2023/07/28</p> <p>13.Any other matters that need to be specified:</p> <p>(1)The convertible bond's stop converting period:2023/06/14~2023/07/11 Last date for bond holders to apply for the conversion:2023/06/12</p> <p>(2)Subsequently, if changes occur to the Company's share capital, affecting the number of shares outstanding, leading to adjustments to the rate of shareholders' dividend distribution, the Company proposes to delegate the Chairman with all competent authority to handle related matters.</p> <p>(3)For the current cash dividend distribution, the dividend will be calculated to the amount of one whole NTD, and any decimal point below one NTD will be rounded down. Shares below one NTD will be adjusted from the largest decimal place, until the total amount of</p>

Date of announcement	Subject	Statement
		cash dividend has been distributed.
2023/06/14	Announcement of the adjustment of the company's cash dividend payout ratio	<p>1.Date of the resolution of the board of directors or shareholders' meeting:NA</p> <p>2.Type and monetary amount of original dividend distribution: Appropriation of earnings in cash dividend:NTD422,522,017/NT\$4.7 per share</p> <p>3.Type and monetary amount of dividend distribution after the change: Appropriation of earnings in cash dividend:NTD422,522,017/NT\$4.69773451 per share</p> <p>4.Reason for the change: Since the convertible bonds' holders requested conversion and the execution of employee stock warrants, the number of the outstanding shares have been changed , and the cash dividend payout ratio needs to be adjusted accordingly.</p> <p>5.Any other matters that need to be specified: Chairman is authorized to adjust cash dividend distribution ratio by the 2023/02/23 Board of Directors.</p>
2023/06/16	Conversion Price adjustment of the privately placed first domestic unsecured convertible bonds	<p>1.Date of occurrence of the event:2023/06/16</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Based on Article 11 of the terms of issuance and conversion of the Company's privately placed first domestic unsecured convertible bonds, the conversion price shall be adjusted on the ex-dividend record date due to distribution of cash dividends. The adjusted conversion price is NT\$266.9.(The conversion price shall be expressed in cents; decimal figures smaller than one cent shall be rounded up or down.)</p>

Date of announcement	Subject	Statement
		<p>6.Countermeasures: The effective date of the conversion price adjustment is 2023/07/11 (the ex-dividend record date).</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.</p>
2023/07/07	Announcement of the Board of Directors to authorize the Chairman to set the record date and matters related to the capitalization of earnings.	<p>1.Date of occurrence of the event:2023/07/07</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: The Chairman was authorized by Board of Directors to set the record date of 2022 dividend distribution and matters related to the capitalization of earnings after the approval from government for the capital increase application.</p> <p>6.Countermeasures:N/A</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.</p>
2023/07/13	To announce the Chairman sets the ex-rights and capital increase record date.	<p>1.Date of the resolution by the board of directors or shareholders' meeting, or of the decision by the company:2023/07/13</p> <p>2.Type (ex-rights or ex-dividend) (please write "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"):Ex-rights</p>

Date of announcement	Subject	Statement
		<p>3.Type and monetary amount of dividend distribution: Stock dividends to common shareholders NT\$206,766,090</p> <p>4.Ex-rights (Ex-dividend) date:2023/08/11</p> <p>5.Last date before book closure:2023/08/14</p> <p>6.Book closure starting date:2023/08/15</p> <p>7.Book closure ending date:2023/08/19</p> <p>8.Ex-rights (Ex-dividend) record date:2023/08/19</p> <p>9.Deadline for applying the conversion of the debt voucher:2023/07/21</p> <p>10.The closure period for the conversion of the debt voucher will start from the date:2023/07/25</p> <p>11.The closure period for the conversion of the debt voucher will end on the date:2023/08/19</p> <p>12.Payment date of cash dividend distribution:NA</p> <p>13.Any other matters that need to be specified:</p> <p>(1)Shareholders can compose a complete share from stock dividends less than one share within 5 days from book closure strating date and these combined shares shall be allocated to one of the shareholders. The stock dividends less than one share after composition or forfeited composition by shareholders will be distributed in cash(removing the fractional part) and the shares will be subscribed by a specific person assigned by the Chairman of the Company who has been authorized by the Board of Directors.</p> <p>(2)The capitalization of retained earings has been approved by Financial Supervisory Commission on 2023/07/13.</p> <p>(3)The convertible bond's stop converting period:2023/07/25~2023/08/19 Last date for bond holders to apply for the conversion:2023/07/21</p> <p>(4)If there are any outstanding shares changed due to the change of the Company's capital stock, the Board of Directors meeting empowers the Charirman to handle.</p>

Date of announcement	Subject	Statement
2023/07/26	Announcement of the adjustment of the company's stock dividend ratio	<p>1.Date of the resolution of the board of directors or shareholders' meeting:NA</p> <p>2.Type and monetary amount of original dividend distribution: Stock dividend:NT\$206,766,090,each common share is entitled to receive NT\$2.3</p> <p>3.Type and monetary amount of dividend distribution after the change: Stock dividend:NT\$206,766,090,each common share is entitled to receive NT\$2.28084606</p> <p>4.Reason for the change: Since the convertible bonds' holders requested conversion and the execution of employee stock warrants, the number of the outstanding shares have been changed , and the stock dividend ratio needs to be adjusted accordingly.</p> <p>5.Any other matters that need to be specified: Chairman is authorized to adjust stock dividend distribution ratio by the 2023/07/07 Board of Directors.</p>
2023/07/27	Conversion Price adjustment of the privately placed first domestic unsecured convertible bonds	<p>1.Date of occurrence of the event:2023/07/27</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Based on Article 11 of the terms of issuance and conversion of the Company's privately placed first domestic unsecured convertible bonds, the conversion price shall be adjusted on the ex-right record date due to distribution of Stock dividend. The adjusted conversion price is NT\$217.3.(The conversion price shall be expressed in cents; decimal figures smaller than one cent shall be rounded up or down.)</p> <p>6.Countermeasures:</p>

Date of announcement	Subject	Statement
		<p>The effective date of the conversion price adjustment is 2023/08/19 (the ex-right record date).</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.</p>
2023/07/28	Notice of company data breach	<p>1.Date of occurrence of the event:2023/07/28</p> <p>2.Cause of occurrence:Certain services of the company were attacked by hacker.</p> <p>3.Handling procedure:Immediately upon detection of the attack, the company's information security team fully activated the relevant defense mechanisms and worked with an external information security company to jointly deal with the attack. The company also notified the occurrence to the relevant government law enforcement authority to assist in handling it. The company will maintain close contact with the law enforcement department and continue to strengthen information security management.</p> <p>4.Anticipated possible loss or impact:No significant impact on operation currently.</p> <p>5.Amount of insurance claims that might be obtained:N/A</p> <p>6.Improvement status and future countermeasures: When the company detects a cyber-attack incidence, it immediately activates information security-related defense mechanisms and response operations. The company will strengthen its anti-fraud warning notice to consumer through text message.The company will also continue to strengthen network information and information security management to ensure data security.</p> <p>7.Any other matters that need to be specified:None.</p>

Date of announcement	Subject	Statement
2023/08/07	Clarification of Media Reports	<p>1.Date of occurrence of the event:2023/08/07</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:Economic Daily News</p> <p>6.Content of the report: The media news headlines 「 Great Tree Pharmacy's will be traded ex-rights on August 11. The legal person estimates that the second quarter EPS will be NTD 2. 」</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by investor news based on the company's released monthly revenue. The actual financial results shall be referred to the Company's official announcements.</p> <p>9.Any other matters that need to be specified:None</p>
2023/08/10	Announcement of the elect for the convener of Audit Committee	<p>1.Date of occurrence of the change:2023/08/10</p> <p>2.Name of the functional committees:Audit Committee</p> <p>3.Name of the previous position holder:Tian-Dao Liu</p> <p>4.Resume of the previous position holder:Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>5.Name of the new position holder:Tian-Dao Liu</p> <p>6.Resume of the new position holder:Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>7.Circumstances of change (Please enter "resignation", "dismissal", "term expired", "death" or "new appointment"):term expired</p>

Date of announcement	Subject	Statement
		8.Reason for the change:term expired 9.Original term (from _____ to _____):2020/06/17~2023/06/16 10.Effective date of the new member:2023/08/10~2026/05/30 11.Any other matters that need to be specified: Audit Committee elected Tian-Dao Liu as the convener of Audit Committee.
2023/08/10	Announcement on the 2023Q2 Consolidated financial report made by Board of Directors	1.Date of the board of directors submitted or approved:2023/08/10 2.Date of the audit committee approved:2023/08/10 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):7,888,456 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,172,621 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):392,504 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):409,718 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):323,826 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):323,682 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.60 11.Total assets end of the period (thousand NTD):10,193,427 12.Total liabilities end of the period (thousand NTD):7,648,903 13.Equity attributable to owners of parent end of the period (thousand NTD):2,520,118 14.Any other matters that need to be specified:NA
2023/08/30	The Company is invited to attend HSBC Taiwan Executive Forum 2023 by	1.Date of institutional investor conference:2023/08/31 2.Time of institutional investor conference:10:00 3.Location of institutional investor conference:Grand Hyatt Taipei

Date of announcement	Subject	Statement
	HSBC	<p>4.Outline of institutional investor conference: The Company is invited to attend HSBC Taiwan Executive Forum event held by HSBC to present operational and financial status.</p> <p>5.Any other matters that need to be specified:None.</p>
2023/09/12	The Company is invited to attend 3Q23 Global Investment Forum held by Yuanta Securities	<p>1.Date of institutional investor conference:2023/09/13</p> <p>2.Time of institutional investor conference:13:30(Taiwan Time)</p> <p>3.Location of institutional investor conference: Regent Taipei 4F (No.3, Ln.39, Sec.2, Zhongshan N.Rd., Zhongshan Dist., Taipei City)</p> <p>4.Outline of institutional investor conference: The Company is invited to attend 3Q23 Global Investment Forum held by Yuanta Securities to present operational and financial status.</p> <p>5.Any other matters that need to be specified:None.</p>
2023/11/10	Announcement on the 2023Q3 Consolidated financial report made by Board of Directors	<p>1.Date of the board of directors submitted or approved:2023/11/10</p> <p>2.Date of the audit committee approved:2023/11/10</p> <p>3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/09/30</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):11,942,606</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):3,286,704</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):588,718</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):612,957</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):487,579</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):487,145</p>

Date of announcement	Subject	Statement
		<p>10. Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): 4.40</p> <p>11. Total assets end of the period (thousand NTD): 10,372,450</p> <p>12. Total liabilities end of the period (thousand NTD): 7,374,065</p> <p>13. Equity attributable to owners of parent end of the period (thousand NTD): 2,977,603</p> <p>14. Any other matters that need to be specified: NA</p>
2023/11/10	Announcement of the Board of Directors approved the establishment of a dedicated Supervisor of Information Security	<p>1. Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development officer, internal audit officer, or designated and non-designated representatives): Supervisor of Information Security</p> <p>2. Date of occurrence of the change: 2023/11/10</p> <p>3. Name, title, and resume of the previous position holder: N/A</p> <p>4. Name, title, and resume of the new position holder: Chiang Chung-Che/Manager of the Company's Information Department</p> <p>5. Type of change (please enter: "resignation", "position adjustment", "dismissal", "retirement", "death" or "new replacement"): new replacement</p> <p>6. Reason for the change: To strengthen the company's information security management mechanism, a dedicated manager is appointed to oversee related affairs.</p> <p>7. Effective date: 2023/11/10</p> <p>8. Any other matters that need to be specified: N/A</p>
2023/11/14	Attending the TPEX Corporate Day	<p>1. Date of institutional investor conference: 2023/11/17</p> <p>2. Time of institutional investor conference: 15:00</p> <p>3. Location of institutional investor conference: Taipei Garden Hotel</p>

Date of announcement	Subject	Statement
		<p>(2F, No.1,Sec.2,Zhonghua Rd.,Zhongzheng District, Taipei City)</p> <p>4.Outline of institutional investor conference: To present Great Tree's operating results and future outlook to the institutional investors.</p> <p>5.Any other matters that need to be specified:None.</p>
2023/11/22	Clarification of Media Reports	<p>1.Date of occurrence of the event:2023/11/22</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:Economic Daily News</p> <p>6.Content of the report: The media news headlines 「 Great Tree Pharmacy withdrawing from carrefour, and UNI-PRESIDENT and PX Mart start a new battle. 」 「 The dispute between UNI-PRESIDENT(1216) and PX Market over the territory of the pharmacy has created a new situation.</p> <p>7.Cause of occurrence: According to recent media reports, the Company has moved out of its cooperative bases in some mass merchandisers.This mainly due to the expiration of the contract.The Company currently has no specific partners to discuss cooperation with. In the future, the Company will still follow the established plan and continue to develop in community lifestyle business districts to serve consumers nearby.</p> <p>8.Countermeasures: In order to prevent investors from misunderstanding,the company specially released this material information and clarified the</p>

Date of announcement	Subject	Statement
		<p>disinformation. Reagarding financial and business information of the company, please refer to announcements and material information on the Marktet Observation Post System.</p> <p>9.Any other matters that need to be specified:None</p>
2023/12/14	Announcement of the elect for the convener of Remuneration Committee	<p>1.Date of occurrence of the change:2023/12/14</p> <p>2.Name of the functional committees:Remuneration Committee</p> <p>3.Name of the previous position holder:Tian-Dao Liu</p> <p>4.Resume of the previous position holder:Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>5.Name of the new position holder:Tian-Dao Liu</p> <p>6.Resume of the new position holder:Certified Public Accountant of Zhi-Dao Accounting Firm</p> <p>7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):term expired</p> <p>8.Reason for the change:term expired</p> <p>9.Original term (from _____ to _____):2020/06/17~2023/06/16</p> <p>10.Effective date of the new member:2023/05/31</p> <p>11.Any other matters that need to be specified:</p> <p>The Remuneration committee is composed of the entire number of independent directors. On December 14,2023,the remuneration committee decided that the chairman and the convener of the Remuneration Committee of the Company is Mr.Tian-Dao Liu.</p>